Today, the SVP & CCO of Vanda (VNDA), Reverberi Gian Piero, sold shares of VNDA for $17.65K.
In addition to Reverberi Gian Piero, 3 other VNDA executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Vanda’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $53.04 million and quarterly net profit of $10.36 million. In comparison, last year the company earned revenue of $44.28 million and had a GAAP net loss of $1.84 million. VNDA’s market cap is $1.06B and the company has a P/E ratio of 43.22. Currently, Vanda has an average volume of 812.5K.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $35.00, reflecting a 76.4% upside.
The insider sentiment on Vanda has been negative according to 19 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
